Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Last trade$1.48
Day change+$0.02 (+1.37%)
Day range$1.38 – $1.55
Volume310,463
Market cap$63M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$62.57M
Price / earnings
—
Price / book
0.72×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.28×
Profitability
Earnings per share
-$1.73
Return on assets
-74.91%
Return on equity
-85.65%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.99×
Quick ratio
7.99×
Cash ratio
3.62×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$64.14M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ACRV, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$4.82M
$4.74M
$5.37M
$6.04M
$6.47M
$6.25M
$6.32M
$6.28M
Research and development
$13.84M
$15.17M
$14.75M
$13.65M
$16.18M
$15.41M
$18.63M
$18.86M
Total operating expenses
$18.67M
$19.9M
$20.12M
$19.69M
$22.65M
$21.66M
$24.95M
$25.14M
Operating income
-$18.67M
-$19.9M
-$20.12M
-$19.69M
-$22.65M
-$21.66M
-$24.95M
-$25.14M
Interest expense
$0
$989K
$0
$0
$0
$2M
$0
$0
Income before taxes
-$17.96M
-$19.04M
-$18.99M
-$18.23M
-$21.01M
-$19.68M
-$22.83M
-$22.44M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$17.96M
-$19.04M
-$18.99M
-$18.23M
-$21.01M
-$19.68M
-$22.83M
-$22.44M
Net income attributable to common shareholders
-$17.96M
-$19.04M
-$18.99M
-$18.23M
-$21.01M
-$19.68M
-$22.83M
-$22.44M
EBITDA
-$18.26M
-$19.52M
-$19.76M
-$19.34M
-$22.31M
-$21.35M
-$24.65M
-$24.89M
Basic earnings per share
-$0.43
-$0.49
-$0.49
-$0.47
-$0.55
-$0.51
-$0.60
-$0.59
Diluted earnings per share
-$0.43
-$0.49
-$0.49
-$0.47
-$0.55
-$0.51
-$0.60
-$0.59
Recent news
Company coverage with links to the original publishers.
Acrivon Therapeutics acquired ACR-525, a Phase 2-ready oral JAK1 inhibitor, and a PKCθ inhibitor preclinical program from Aqilion AB for undisclosed cash consideration. The acquisition establishes immunology and inflammation as a strategic pillar alongside oncology, with eosinophilic esophagitis targeted as the first indication. Acrivon's AP3 platform profiling characterized ACR-525 as a highly selective, potentially best-in-class JAK1 inhibitor with broad potential in IBD and other autoimmune disorders.
Acrivon Therapeutics announced preclinical data showing strong synergies between its lead assets ACR-368 (CHK1/2 inhibitor) and ACR-2316 (WEE1/PKMYT1 inhibitor) when combined with anti-PD-L1 checkpoint inhibitors and ADC payloads. The company will present three posters at the AACR 2026 Annual Meeting in San Diego, demonstrating potent efficacy and durable immune memory in combination therapies, supporting potential frontline clinical development opportunities.
Acrivon Therapeutics announced three poster presentations at the 2026 AACR Annual Meeting showcasing preclinical data demonstrating strong synergy of ACR-368 (CHK1/2 inhibitor) with Topoisomerase 1 inhibitor ADC payloads, and synergy of both ACR-368 and ACR-2316 (WEE1/PKMYT1 inhibitor) with immune checkpoint inhibitors. The data highlight the company's AP3 platform's ability to identify therapeutic candidates and combinations with clinical potential.
A comprehensive report reveals over 50 companies are developing 55+ pipeline drugs for endometrial cancer, focusing on advanced therapies and improving treatment paradigms for postmenopausal women.
Acrivon Therapeutics reported positive data from its ongoing Phase 2 study of ACR-368 in endometrial cancer, with a confirmed overall response rate of 62.5% in OncoSignature-positive patients. The company also disclosed the IND clearance and activation of initial clinical sites for its next candidate, ACR-2316, ahead of schedule.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.